DAM
VIRX

Doheny Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Doheny Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-371
Closed -$9K – 99
2019
Q3 		$9K Sell
371
-286
-44% -$8.25K 0.01% 91
2019
Q2 		$17K Buy
+657
New +$25.4K 0.01% 92

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Doheny Asset Management's VIRX Position: Q4 2019 in Review

Doheny Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2019, closing a stake of 371 shares — an estimated $9K sold.

Doheny Asset Management first reported a position in VIRX in Q2 2019 and held it in 2 quarters. The position peaked at $17K in Q2 2019. 44 funds tracked by Wall St. Rank hold VIRX as of Q4 2019.

  • Doheny Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Doheny Asset Management sold 371 Viracta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $9K.
  • Doheny Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Doheny Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $17K in Q2 2019.
  • 44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Doheny Asset Management's 13F filing for Q4 2019, filed 11 Feb 2020.